Oncology Views & Analysis

Views & Analysis

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Changing focus to cachexia may be key to improved cancer out...

Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr.

Views & Analysis

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

New Cell & Gene Therapy Collective seeks to boost UK adoptio...

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to

Views & Analysis

Can in vivo imaging deliver the full potential of immunotherapy

The next generation of immunotherapy? Innate Pharma targets ...

Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer.

Digital

Country focus: Hungary carves out a niche in digital pharma

AI simulated cell company Turbine is just one of many digital drug discovery firms on the rise in Hungary.

Market Access

Lymphoma Action – championing the patient voice in cell ther...

Lymphoma Action is the only UK health charity dedicated to people affected by lymphoma.

Videos

Health Innovators: Owlstone Medical's Billy Boyle on breath ...

In the latest episode of our Health Innovators series, Paul Tunnah speaks to Billy Boyle, co-founder and CEO of Owlstone Medical, one of the UK’s most promising diagnostic startups.

Changing focus to cachexia may be key to improved cancer out...

New Cell & Gene Therapy Collective seeks to boost UK adoptio...

The next generation of immunotherapy? Innate Pharma targets ...

Country focus: Hungary carves out a niche in digital pharma

Lymphoma Action – championing the patient voice in cell ther...

Health Innovators: Owlstone Medical's Billy Boyle on breath ...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks